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Occlusive arterial thrombosis leading to stroke and myocardial infarction contribute to 
~13 million global deaths annually. In 1995, Intravenous recombinant tissue plasminogen 
activator (rTPA) represented a breakthrough in stroke therapy, reducing morbidity and 
improving functional outcomes.2 However, it was found that patients treated with rTPA routinely 
result in inadequate recanalization in the setting of large vessel occlusion, experienced 
restenosis, and suffered from symptomatic intracranial hemorrhage (ICH).2 Moreover, given that 
patients must receive rTPA within 3 to 4.5 hours from symptom onset and not have one of the 
18-point exclusion criteria, only ~6% of patients received rTPA of the 690,000 ischemic stroke 
incidents that occurred in 2017.1-3  Given all of this, a change from the current stroke 
therapeutics must be investigated to improve safety and efficacy.  
Aptamers are single-stranded oligonucleotides (RNA and DNA) that can bind to and 
inhibit targeted proteins. Unlike rTPA and parenteral anti-platelet drugs, aptamers can be 
reversed with antidote oligonucleotides, that bind to the aptamer via Watson-Crick base-pairing 
without perturbing platelet reactivity. In this study, we propose a paradigm shift from the current 
stroke therapeutics to a new target resulting in a more effective, safer, and readily reversible 
anti-thrombotic agent. Our laboratory has developed an RNA aptamer therapeutic (DTRI-031) 
which directly inhibits von Willebrand Factor (VWF)-mediated platelet adhesion and 
aggregation. Along with a matched antidote DTRI-025 to control its activity, we demonstrate that 
DTRI-031 can lyse stabilized clots in a safer and more effective fashion than rTPA. 
Furthermore, the information included in this project can provide considerable insight into the 





A. Historical Background  
According to data from the National Stroke Association, cerebrovascular disease 
(stroke) is the fifth leading cause of death in the United States with more than 800,000 
Americans experiencing a new or recurrent stroke each year. Every 40 seconds a patient 
suffers a stroke and every 4 minutes a stroke is fatal.1 Stroke can be classified into two separate 
categories, hemorrhagic or ischemic. Hemorrhagic stroke is caused by the rupture of blood 
vessels within the brain, whereas ischemic stroke is caused by a blockage within a vessel 
preventing oxygen and nutrients from reaching the brain. Of all strokes presented clinically, 87% 
have been identified as ischemic. Intravenous recombinant tissue plasminogen activator (rTPA) 
has been the mainstay of therapy for ischemic stroke treatment since 1995. While the 
therapeutic window was extended to 4.5 hours from symptom onset, rTPA therapy remains 
limited to 5-10% of stroke patients with a 6.4% hemorrhagic rate and dismal recanalization 
rate.1,2  
An additional class of drugs have been studied in stroke targeting GPIIb/IIIa, one of the 
key integrins involved in platelet aggregation and, therefore, blood clot formation; Abciximab, 
Eptifibatide and Tirofiban. All 3 drugs are used in treating cardiovascular disease but have 
resulted in poor outcomes in the brain related to uncontrolled hemorrhage.  
More recently, clinical trials have demonstrated endovascular thrombectomy with stent 
retrievers resulted in superior neurological outcomes compared to rTPA in patients who present 
with large vessel occlusion (LVO).3,4 This is defined as a clot in the internal carotid artery (ICA) 
segment of the brain, known as a the supraglenoid ICA, or a clot in the first segment of the 
middle cerebral artery (M1) or anterior cerebral artery (A1). 
In patients who develop a significant stroke with edema, a hemicraniectomy can be 
performed to reduce mortality and modestly improve neurological outcome.6 Despite all the 
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listed acute and subacute therapies, stroke remains the single largest cause of morbidity and 
mortality in the world today.3-5  Therefore, an urgent need exists to improve the morbidity and 
mortality of ischemic stroke. 
 
B. Hemostasis and Coagulation 
Understanding blood clot formation is critical to identifying an optimal target for stroke 
treatment. Normal hemostasis, considered the first stage of wound healing, is the result of well-
regulated steps to prevent hemorrhage and maintain blood in a clot-free state in vessels. After 
vascular injury, coagulation is initiated by rapidly localizing circulating platelets to the site of 
injury. The exposed extracellular matrix of the injured vessel creates a highly thrombogenic 
environment which causes circulating platelets to become activated and adhere to the damaged 
endothelium. Specifically, the subendothelial von Willebrand Factor (VWF) that is exposed as a 
result of vascular injury binds to the platelet expressed GP Ib-IX-V, resulting in platelet 
activation and adhesion to the damaged endothelial surface.7 In response to platelet activation, 
secretory granules are released, inducing aggregation of additional platelets to form a 
hemostatic plug.7,8 Altogether, the interaction between coagulation factors in platelets is crucial 
to the formation of a thrombus.  
Coagulation can be understood from two different mechanisms of hemostasis: the first is 
a clotting cascade which demonstrates clotting as two separate pathways consisting of 
sequential steps of activation to form a common pathway; the second is a cell-based model of 
coagulation which centers on coagulation occurring on the platelet surface.7 While the classical 
model of the coagulation cascade correlates well with laboratory tests and describes clotting 
neatly with an intrinsic and extrinsic pathway, it fails to properly describe coagulation in vivo. 
The cell-based model of coagulation illustrates the formation of a blood clot in three overlapping 




C. von Willebrand Factor  
Von Willebrand Factor (VWF) is a large multimeric glycoprotein involved in the seminal 
event of platelet plug formation.9,10 When vascular injury occurs, subendothelial collagen 
becomes exposed to the circulating blood, allowing VWF to serve as a “bridge” between the 
exposed collagen and platelets as well as between platelets themselves.9 In particular, VWF 
interacts with glycoprotein Ibα on platelets to induce adhesion to the vessel wall. Following this, 
glycoprotein IIb/IIIa becomes activated, binds to fibrinogen, and results in aggregation and 
thrombus formation (Figure 1).  
Numerous studies have indicated that the risk of myocardial infarction and stroke 
correlate with VWF levels among patients at risk.17,18 Inhibitors of VWF have shown promise to 
limiting thrombosis,19-22 however their effect on hemostasis can lead to significant bleeding in 
the surgical setting.21-23 In response to this, patients in need of platelet inhibition in the 
perioperative setting would benefit from a rapidly controllable VWF inhibitor. Furthermore, Von 
Willebrand Disease (VWD), resulting from a qualitative and/or quantitative reduction in VWF, 
presents with menorrhagia in women or bleeding in patients undergoing dental procedures, but 
rarely results in spontaneous hemorrhage.11 Most importantly, patients with VWD are protected 
from cerebrovascular and cardiovascular events; therefore VWF, often overlooked, is an 
attractive target for disorders resulting from arterial thrombosis.12 
 
D. Aptamers  
Aptamers are a class of DNA or RNA ligands that act like protein inhibitors much like 
monoclonal antibodies and small molecules.13 They function by folding into 3-D structures, 
binding to and inhibiting the function of target proteins with high affinity and specificity. Aptamers 
are isolated by systematic evolution of ligands by exponential enrichment (SELEX) (Figure 2).  




While most anti-thrombotic therapeutics routinely come with the risk of hemorrhage due 
to lack of reversibility, antithrombotic aptamers can be regulated by antidote oligonucleotides. 
By binding the aptamer with Watson-Crick base pairing, the antidote oligonucleotide prevents 
the aptamer from inhibiting its target protein. In preclinical studies, an antidote oligonucleotide 
for an aptamer inhibiting coagulation factor IXa (FIXa) showed rapid and complete reversal in 
less than 5 min after administration.13,14 With the ability to reverse activity in the setting of 
hemorrhage in addition to unlimited shelf life, and low to no immunogenicity, aptamers show 
promise to treat thrombosis.14  
 
E. Project Overview  
As previously described, VWF is a novel and attractive target to exploit for anti-
thrombotic therapeutics as it plays a pivotal role in platelet adhesion, activation and aggregation. 
Our laboratory has developed an RNA aptamer therapeutic (DTRI-031) which binds VWF and 
inhibits its molecular interaction with the platelet-expressed glycoprotein Ib-IX-V surface 
receptor, preventing platelet adhesion and aggregation.6,9 In addition, a matched antidote was 
developed (Figure 3) allowing precise, rapid, and complete reversal of the aptamer in vivo, an 
element not available in current anti-platelet therapies.9  
rTPA has improved morbidity and mortality in acute ischemic stroke, but hemorrhage 
risk decreases treatment time to <4.5 hours after symptom onset. In the setting of large vessel 
occlusion stroke, where patients undergo endovascular thrombectomy, restenosis and 
thrombosis attributed to subendothelial injury and exposure of VWF during current mechanical 
thrombectomy therapy results in significant morbidity and mortality.3,4 Targeting VWF and 
inhibiting its interaction with GP Ib-IX-V would not only prevent thrombus initiation and platelet 
aggregation, but can also recanalize a stabilized clot.  In addition, the matched aptamer antidote 
provides an invaluable tool to limit potentially catastrophic intracranial hemorrhage and expand 
the current treatment window. By utilizing a clinically-relevant stroke model of middle cerebral 
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arterial occlusion (MCAO), we aimed to determine the thrombolytic efficacy of DTRI-031 in small 
and large animals by comparing cerebral reperfusion, resulting hemorrhage and stroke volumes 
to the established rTPA protocol. Consequently, we aimed to demonstrate that DTRI-031 can 
lyse stabilized clots in a safer and more effective fashion than rTPA. Furthermore, the 
knowledge of the impact of antithrombotic aptamers may lead to the potential replacement of 
the current stroke therapeutic paradigm with DTRI-031 for all patients who present with stroke 
symptoms at any time after symptom onset.  
          
III. MATERIALS AND METHODS  
 
Animals 
All experiments were approved by The Ohio State University Institutional Animal Care 
and Use Committee. Wild-type (WT) C57/BL6 adult mice (8-16 weeks of age) and adult canine 
beagles (>1 year old) were obtained from Jackson Laboratory and Covance respectively. Mice 
(n=30; 5 per group male & female) were group housed in a 12:12 light/dark cycle on ventilated 
racks in a temperature and humidity-controlled vivarium with filtered tap water and ad libitum 
access to food (standard chow). Beagles (n=12; 4 per group), were group housed in a 
temperature and humidity-controlled vivarium at Wiseman Hall and maintained by ULAR staff. 
 
Middle Cerebral Arterial Occlusion  
 Acute ischemic stroke was induced by thrombin activation of an autologous clot.15,16 
Mice were anesthetized using a mixture of 55 mg/kg ketamine and 15 mg/kg xylazine. Body 
temperature was maintained at 37 C using a thermo-regulated heating pad and baseline vital 
sign, blood pressure (CODA) and heart rate (LabChart) were recorded. An incision in the left 
saphenous vein and insertion of an intravascular catheter allowed for treatment delivery. An 
intracranial catheter was inserted into the middle cerebral artery (MCA) containing a mixture of 1 
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uL of purified mouse thrombin, 13 uL of sterile saline, and autologous blood. Stabilized for 15 
minutes, the clot was introduced into the MCA. After 20 minutes, treatment was administered 
using either DTRI-031 (50 uL bolus over 5 min followed by vehicle (PBB+) at 2 ul/min for 40 
min), TPA (10 mg/kg or 2 mg/kg at 2ul/min infused over 45 min), or vehicle (PBB+ at 2 ul/min for 
45 min) (Figure 4). Blood pressure and heart rate were monitored at perfusion start/stop and at 
sacrifice. At 24 hours following MCAO, mice were sacrificed, and tissues were harvested for 
histopathologic evaluation.  
 Endovascular basilar artery occlusion (BAO) materials and methods were optimized in 
beagle canines.15 Preliminary data collected on this procedure has indicated that canine vessel 
anatomy complicates MCA occlusion. As a result, the basilar artery (BA) was occluded by 
inserting an intracranial catheter through the femoral artery and introducing an autologous clot. 
On the day of surgery, beagles were sedated with telazol and anesthetized (isoflurane) and 
ventilated. Body temperature, end-tidal CO2 and continuous cardiac rhythm monitoring were 
recorded and maintained within physiologic range. A 1 cm2 cranial window above the 
cerebellum was created for laser speckle imaging and an autologous clot was produced by 
mixing 0.5 g Barium Sulfate and 5 mL autologous whole blood. Bilateral common femoral artery 
entrance was achieved percutaneously by utilizing 5-French sheaths.15 With fluoroscopic 
guidance (GE Medical OEC 9800 Plus Cardiac) a guide catheter, connected to pressurized 
normal saline, was advanced into (1) vertebral artery.15 Following this, arteriographic evaluation 
of the vertebrobasilar arterial system was performed by placing a 4-French catheter through the 
sheath at the contralateral puncture site during clot deployment. A microcatheter (Boston 
Scientific, SL-10), through the vertebral artery guide catheter, was then guided by a microwire 
(Boston Scientific, synchro2 soft) and progressed and tracked into the basilar artery.15 After the 
microcatheter was in place, it was manipulated to deliver a 2 mL autologous clot to occlude the 
BA. Successful BA occlusion was determined angiographically and the total occlusion time was 
60 minutes. At 16 frames per second, arteriograms were acquired to evaluate the 
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vertebrobasilar system using 4 mL aliquots of iohexol (Omnipaque 300, GE Healthcare) injected 
through the 4-French catheter at the time of occlusion and immediately before drug 
administration to confirm occlusion.15 After clot stabilization, treatment was administered 
intravenously over 45 minutes using either DTRI-031 (0.5 mg/kg), TPA (0.9 mg/kg), or PBB+ (2 
mL/min). At 3 hours following occlusion, arteriograms were acquired to evaluate extent of 
reperfusion. Beagles were then sacrificed, and necropsy was performed to isolate the brain for 
histopathologic evaluation (Figure 5-6). 
 
Visualization of Thrombus In Vivo  
 Acute ischemic stroke is the result of a sudden occlusion in an arterial vessel which 
restricts cerebral blood flow and delivery of nutrients including glucose and oxygen to brain 
tissue. To model this phenomenon in vivo, we employed an autologous clot by inserting a 
catheter into the basilar artery of beagles. Digital subtraction angiography was performed on 
beagles to verify successful basilar artery occlusion and reperfusion. Using a long flexible 
catheter to steer through the blood vessels, a contrast agent (Omnipaque 300, GE Healthcare) 
was delivered into the arteries, making them visible on the x-ray monitor. A fluoroscope machine 
(GE OEC 9800 Plus) was utilized to perform this procedure by generating x-rays from one side 
and photographing them on the other side. The contrast used allows the blood vessels to be 
visible on the monitor, creating a roadmap of the arteries of interest. Digital subtraction 
angiography was performed at baseline, after injection of clot to validate successful occlusion, 
60 minutes after bolus stop, and at sacrifice.  
 
Measurement of Perfusion and Vasculature  
To determine the extent of cerebral flow in beagles, laser speckle imaging was 
performed at baseline, during injection of clot, throughout treatment, and at sacrifice. Due to the 
limited depth of the laser, a 1 cm2 cranial window above the cerebellum was created to improve 
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the contrast analysis in the region of interest. By generating patterns of reflected light from 
within the cranial window, the laser speckle imaging device is able to differentiate between 
stationary and moving particles. With an integrated algorithm using perfusion units (pu) to 
measure blood flow, stationary particles were calculated around 0 pu and were shown as blue 
while moving particles were calculated around 200 pu and were shown as red.  
 
Quantification of Stroke and Hemorrhage Volumes 
At time of sacrifice, T2 weighted Magnetic Resonance Imaging (MRI) was performed on 
both mice and beagles to access infarction volumes and downstream thromboembolic events. A 
Philips 3T MRI scanner (Philips Ingenia CX 3T MRI, Best, Netherlands) was used to acquire MR 
images for canines using the “Knee coil” (Philips dStream 16 channel Knee coil) as a receiver 
coil with SENSE enhanced parallel imaging performance. Beagles were anesthetized using 
isoflurane and positioned head-first supine. MRI scanning parameters used were: T1W: FOV 
130 mm, Matrix size 320 x 320, Slice thickness =3 mm, TR= 500 ms, FA= 150 degrees, BW 
=255 Hz/pixel, NEX= 1, TE=22ms, Resolution= 2.4615 pixels per mm. T2W-TSE: FOV 130 mm, 
Matrix size 320 x 320, Slice thickness =3 mm, TR= 4000 ms, FA= 180 degrees, BW =255 
Hz/pixel, NEX= 2, TE=75ms, Resolution= 2.4615 pixels per mm; T2W-FLAIR: FOV 130 mm, 
Matrix size 320 x 320, Slice thickness =3 mm, TR= 4000 ms, FA= 180 degrees, BW =255 
Hz/pixel, NEX= 2, TE=75ms, Resolution= 2.4615 pixels per mm; DWI: FOV 149x149 mm, 
Matrix size 132 x0x0x 100, Slice thickness =4 mm, TR= 4600 ms, FA= 90 degrees, BW =255 
Hz/pixel, NEX= 1, TE=86ms, Resolution= 0.9333 pixels per mm; DICOM images were 
transferred for post-processing and OsiriX MD v.5.0 software was used to post process the 
DICOM series. Two sets of images with b = 0 and 1800 s/mm2 was used to calculate ADC 
maps. In addition, coronal sections of the cerebrum in the canine brain were stained with 
triphenyl-2,3,5-tetrazolium-chloride (TTC) as well as hematoxylin and eosin (H&E) to verify 
percent reperfusion and infarct volumes. Reaction in metabolically active cells turn red when 
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placed in TTC, whereas dead cells will not display color. Sections stained with TTC were 
scanned with a high-resolution scanner and infarct areas (white) were compared with the region 
of infarct in MRI. Hematoxylin and Eosin (H&E) staining demonstrates live versus dead cells 
and was also compared to TTC & MRI infarct areas and microembolism.  Sections stained with 
H&E were scanned with a high-resolution slide scanner.  
 
Data Analysis 
 The results of the experiments were analyzed by several statistical methods using 
standard software programs (EXCEL, GraphPad Prism) and expressed as mean ± standard 
deviation. For comparison between two groups, significance will be determined by paired or 
unpaired Student t test. For comparison of multiple groups, multifactorial ANOVA with post hoc 
comparison will determine significance. For all data analysis, probability values of p < 0.05 were 




Aptamer DTRI-031 significantly improves stroke outcome in a murine model of middle 
cerebral arterial occlusion  
To assess its effectiveness as a thrombolytic agent, we administered DTRI-031 in a 
murine middle cerebral arterial occlusion stroke model. The primary endpoint of this animal 
model is to evaluate the thrombolytic activity of DTRI-031 and compare it to rTPA, the most 
widely used thrombolytic drug and the mainstay of therapy in acute ischemic stroke.  After 
intubation and sedation, the left saphenous vein was exposed and catheterized for treatment 
delivery. An intracranial catheter was then inserted into the middle cerebral artery (MCA) 
containing a mixture of 1 uL of purified mouse thrombin, 13 uL of sterile saline, and autologous 
blood to generate a thrombus. Following 15 minutes of stabilization, the clot was introduced into 
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the MCA. Once total occlusion had been verified by cessation of blood flow, the occlusive 
thrombus was left to stabilize for an additional 20 minutes and then aptamer DTRI-031, rTPA, or 
vehicle (PBB+) was administered. In this experiment, rTPA was dosed at 10 mg/kg which is 11-
fold higher than 0.9 mg/kg (the clinical dose administered to human patients who present with 
ischemic strokes <4.5 hours from symptom onset) because this was the dose reported to be 
effective for recanalization in murine stroke models. Aptamer DTRI-031 was dosed at 0.5 
mg/kg. Following thromboembolic stroke, significant ischemic stroke volumes involving the MCA 
territory were identified in 81.4% of control-treated animals and in 14.8% of animals treated with 
DTRI-031 (p<0.05) (n=10 per group) (Figure 7). Ischemic stroke volumes were significantly 
higher in animals treated with saline control (7.829 ± 1.988 mm3) and rTPA (5.362 ± 1.441 mm3) 
compared to animals treated with DTRI-031 (1.557 ± 0.5131 mm3) (p<0.05) (n=10 per group) 
(Figure 7). There was no hemorrhagic conversion identified in either cohort.  
 
Aptamer DTRI-031 demonstrates greater cerebral reperfusion in a canine model of 
thromboembolic stroke compared to rTPA  
 A canine model of cerebrovascular thrombotic disease was used to corroborate the 
murine results in a large, clinically relevant animal. Adult beagles were intubated and sedated. 
The right cephalic artery was catheterized for drug administration and the right femoral artery 
was catheterized for clot delivery. A 1 cm2 cranial window above the cerebellum was created for 
laser speckle imaging and a microcatheter was inserted into the basilar artery for clot delivery. 
An autologous clot was created by mixing 0.5 g Barium Sulfate and 5 mL autologous whole 
blood. Arterial occlusion was indicated by laser speckle imaging and verified by digital 
subtraction angiography of the basilar artery (Figures 8). After 60 minutes of occlusion, animals 
received one of 3 agents: 1) Intravenous injection of 0.5 mg/kg DTRI-031 as a bolus, 2) 
Intravenous injection of 0.9 mg/kg of rTPA by the standard clinical protocol of 10% injection 
followed by 90% infusion over 45 minutes, and 3) Intravenous injection of vehicle (PBB+) at 2 
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mL/min over 45 minutes. No significant difference in baseline cerebellar perfusion was 
measured between treatment groups (n=4 per group) using laser speckle imaging (LSI). 
However, induction of BAO injury caused a 58.7 ± 20.2%, 68.7 ± 22.5%, and 70.0 ± 15.5% 
decrease in perfusion in vehicle, rTPA, and DTRI-031, respectively. DTRI-031 treated animals 
resulted in 50.0 ± 32.3% of baseline perfusion restored, compared to rTPA with 38.9 ± 38.6% at 
3 hours after BAO (Figure 9). Images assessed by LSI further revealed 0.5 mg/kg DTRI-031 
resulted in a greater percentage of baseline flow restored after injury compared to 0.9 mg/kg 
rTPA (Figure 10). Visualization of perfusion through digital subtraction angiography verified 
canines treated with DTRI-031 resulted in greater reperfusion before sacrifice compared to 
rTPA or vehicle (Figures 11A—C).  
 
Aptamer DTRI-031 demonstrated reduced infarct volume and no brain hemorrhage or 
embolization in canines  
To evaluate the safety and efficacy of DTRI-031, T2-weighted Magnetic Resonance 
Imaging (MRI) was performed at time of sacrifice to compare infarction volumes and 
downstream thromboembolic events to rTPA and vehicle control. In addition, a coronal section 
of the cerebrum was stained with triphenyl-2,3,5-tetrazolium-chloride (TTC) as well as 
haematoxylin and eosin (H&E) to verify percent reperfusion and infarct volumes. Dogs were 
anesthetized using isoflurane and positioned head-first supine. A Philips 3T MRI scanner 
(Philips Ingenia CX 3T MRI, Best, Netherlands) was used to acquire MR images using the 
“Knee coil” as a receiver coil with SENSE enhanced parallel imaging performance. DICOM 
images were transferred for post-processing and OsiriX MD v.5.0 software was used to post 
process the DICOM series. Two sets of images with b=0 and 1800 s/mm2 were used to 
calculate ADC maps. Stroke regions were traced with a red dotted line that matched the stroke 
region on histological (TTC stained) images (Figure 12B).  Although the preliminary data 
collected has provided results for only one canine brain (treated with rTPA, n=1), rTPA 
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administration induced an infarction volume of 59.91 mL while leaving only 65.67 mL of normal 
brain tissue. Infarct percentage was calculated at 61.51% for rTPA administration in adult 
beagle canines (n=1) (Figure 12A—B). Histological comparison of treatments (Figure 13A—F) 
confirmed smaller infarction with DTRI-031 compared to rTPA and vehicle. Neither DTRI-031, 
nor rTPA or vehicle resulted in intracranial hemorrhage or thromboembolic events at time of 
sacrifice (3 hours after injury) by H&E staining (Figure 13D—F). Furthermore, post-reperfusion 
arteriograms (Figure 11B) confirmed reperfusion with DTRI-031 administration with no 
evidence for peripheral thrombotic events. rTPA and vehicle resulted in no reperfusion before 
sacrifice (Figure 11B, C).  
 
Aptamer DTRI-031 demonstrated no deleterious effects on animal physiology 
Mice and beagle vital signs (blood pressure and heart rate) were recorded to assure 
normal physiological conditions (cardiac function) during the entire surgical procedure and 
treatment administration. No significant difference was found in mean blood pressure or heart 
rate between treatment groups (DTRI-031, rTPA, or vehicle) in mice (Figures 14A—B) and in 
beagles (Figure 15A—D). All treatment groups in both mice and beagles resulted in normal 




The motivation for ischemic stroke research is driven by the fact that current thrombolytic 
therapy treats only 6% of the over 690,000 stroke patients, while endovascular thrombectomy 
treats another 15% of patients.  The majority of those who suffer ischemic strokes receive no 
acute therapy. Although rTPA represented a breakthrough, reducing morbidity and improving 
functional outcomes, rTPA cannot be reversed, and at 6.4%, the risk of hemorrhagic conversion 
is significant.2,4 Second, restenosis and occlusion can occur after initial thrombolysis, reversing 
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initial neurological improvement. Finally, a narrow temporal window to administer rTPA excludes 
a significant fraction of patients who suffer ischemic cerebrovascular insults (~90%).4 Several 
additional stroke therapeutics have been investigated in the past 20 years and while they have 
shown promise in pre-clinical testing, only a few have been effective in a clinical setting.25 Due 
to this urgent need for therapeutic options to treat ischemic stroke patients, we set about testing 
the efficacy of inhibiting VWF using an RNA aptamer (DTRI-031) against ischemic stroke.  
VWF plays an important role in not only platelet adhesion at a site of endothelial injury or 
atheromatous plaque, but also assists in platelet aggregation and cross-linking through its 
association with GP IIb/IIIa receptors.10 Elevated VWF levels are known to place patients at a 
higher risk of ischemic stroke23, and VWF inhibition has been shown to ameliorate stroke 
severity following transient MCAO in pre-clinical models.26,27 Given the central role of VWF in 
thrombus initiation and propagation, it represents an attractive target for both thrombolysis and 
prevention of secondary thrombosis and re-occlusion.  
In previous studies, DTRI-031 inhibition of VWF has demonstrated efficacy as a potent 
anti-platelet agent with the ability to prevent thrombus formation in vivo.8 In this study we aimed 
to investigate the thrombolytic efficacy of DTRI-031 by utilizing clinically relevant stroke models 
with small and large animals. In the murine middle cerebral artery occlusion model, we 
demonstrated a significant decrease in stroke volume in DTRI-031 treated mice compared to 
rTPA and control (Figure 7). No deleterious effects on mice physiological conditions were 
recorded during DTRI-031 treatment (Figure 14).  We then aimed to corroborate the murine 
results in a large, clinically relevant animal. Using a canine model of cerebrovascular thrombotic 
disease, we occluded the basilar artery in beagles and investigated the thrombolytic efficacy of 
DTRI-031 by comparing it to rTPA and control. We found that Inhibition of VWF by DTRI-031 
resulted in greater restoration of perfusion compared to rTPA and control at 60 minutes after 
placement of an autologous clot (Figures 9-11). Additionally, DTRI-031 treated canines showed 
less infarction with no evidence of thromboembolism, results reflected in our murine MCAO 
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experiments (Figure 13). No deleterious effects on beagle physiological conditions were 
recorded during DTRI-031 treatment (Figure 15). 
The preliminary results presented in this study demonstrate that DTRI-031 inhibition of 
VWF is an effective anti-thrombotic agent in both small and large animal models of 
thromboembolic stroke. With further investigation and data analysis, we believe VWF inhibition 
by DTRI-031 may represent a replacement for rTPA therapy for the >90% of stroke patients 
who are left with little thrombolytic options. Moreover, we believe that the antidote-controlled 
approach we have developed, taken together with the highly potent antithrombotic and 
thrombolytic efficacy of the VWF aptamer DTRI-031, could provide an effective and safer 
treatment option not only in acute ischemic stroke, but may be generalizable to coronary and 
peripheral artery disease as well.  
 
Table 1 
Experimental Outcomes Murine Canine 
Magnetic Resonance Imaging (stroke and hemorrhage 
volumes)  
✓ ✓ 
Angiography (extent of occlusion and reperfusion)  ✓ 
Speckle (blood flow velocity throughout the brain)   ✓ 
Histology (H&E staining and TTC staining to verify MRI) ✓ ✓ 
Physiological Effect (Verify physiological surgery conditions 









Figure 1: The interaction between Von Willebrand Factor (VWF) and glycoprotein Ib-IX-V (gpIb-


































Figure 2: Systematic evolution of ligands by exponential enrichment (SELEX). Technique used 
in molecular biology for producing oligonucleotides of either single-stranded DNA or RNA that 















Figure 3: Antidote oligonucleotide (DTRI-025) binds to VWF aptamer (DTRI-031) by Watson Crick 







Figure 4: Murine treatment groups (n=30). Equal number of male and female mice distributed into 




































Figure 6: Protocols for in vivo canine experiments. Cerebral flow was recorded and stabilized for 
a period of 5 min with continuous ECG, heart rate, and blood pressure monitoring throughout. 





Figure 7: Stroke volume was significantly decreased in mice treated with VWF aptamer (1.557 ± 















Figure 9: BA perfusion measured by Laser Speckle Imaging (LSI). Beginning with no significant 
difference in baseline cerebellar perfusion, induction of BAO injury caused a 58.7±20.2%, 
68.7±22.5%, and 70.0±15.5% decrease in perfusion in vehicle, rTPA, and DTRI-031, respectively. 
DTRI-031 resulted in 50.0±32.3% of baseline perfusion restored, compared to rTPA with 







Figure 10: Laser Speckle Imaging (LSI) comparison of DTRI-031 and rTPA treatments. 0.5 mg/kg 
VWF aptamer resulted in a greater percentage of baseline flow restored 3 hours after injury in 
Male Dog 7 (CJACAK) (A) compared to 0.9 mg/kg rTPA in Male Dog 4 (CJACLJ) (B) assessed 






Figure 11: Digital Subtraction Angiography images comparing extent of occlusion and reperfusion 
between treatments. 0.5 mg/kg VWF aptamer resulted in greater reperfusion at sacrifice in Male 
Dog 7 (CJACAK) (B) compared to 0.9 mg/kg rTPA in Male Dog 4 (CJACLJ) (A) or saline control 








Figure 12: Preliminary data showing quantification of stroke and hemorrhage volume. rTPA 
administration on Male Dog 4 (CJACLJ) induced an infarction volume of 59.91 mL (61.51% 
infarct) (A). Representative image of T2-weighted high-resolution magnetic resonance imaging 
after MCAO was induced in Male Dog 4 (CJACLJ) treated with rTPA (B). A Philips 3T MRI scanner 
(Philips Ingenia CX 3T MRI, Best, Netherlands) was used to acquire MR images using the “Knee 
coil” (Philips dStream 16 channel Knee coil) as a receiver coil with SENSE enhanced parallel 
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imaging performance. Dog was anesthetized using isoflurane and was positioned head-first 
supine. MRI scanning parameters used were:T1W: FOV 130 mm, Matrix size 320 x 320, Slice 
thickness =3 mm, TR= 500 ms, FA= 150 degrees, BW =255 Hz/pixel, NEX= 1, TE=22ms, 
Resolution= 2.4615 pixels per mm. T2W-TSE: FOV 130 mm, Matrix size 320 x 320, Slice 
thickness =3 mm, TR= 4000 ms, FA= 180 degrees, BW =255 Hz/pixel, NEX= 2, TE=75ms, 
Resolution= 2.4615 pixels per mm; T2W-FLAIR: FOV 130 mm, Matrix size 320 x 320, Slice 
thickness =3 mm, TR= 4000 ms, FA= 180 degrees, BW =255 Hz/pixel, NEX= 2, TE=75ms, 
Resolution= 2.4615 pixels per mm; DWI: FOV 149x149 mm, Matrix size 132 x0x0x 100, Slice 
thickness =4 mm, TR= 4600 ms, FA= 90 degrees, BW =255 Hz/pixel, NEX= 1, TE=86ms, 
Resolution= 0.9333 pixels per mm; DICOM images were transferred for post-processing and 
OsiriX MD v.5.0 software was used to post process the DICOM series. Two sets of images with 
b = 0 and 1800 s/mm2 was used to calculate ADC maps. Stroke region is traced with a red dotted 







Figure 13: Histological comparison of treatments. TTC staining of canine brain confirmed smaller 
infarction with DTRI-031 (A) compared to rTPA (B) and vehicle (C). Neither DTRI-031 (D), nor 
rTPA (E) or vehicle (F) resulted in intracranial hemorrhage or thromboembolic events at time of 







Figure 14: Physiological comparison of treatments in a murine model of thromboembolic stroke. 
No significant difference in blood pressure (A) or heart rate (B) was recorded between treatments 





Figure 15: Physiological comparison of treatments in a canine model of thromboembolic stroke. 
No significant difference was recorded between treatments during continuous blood pressure 
monitoring (mean blood pressure) (A) or in mean blood pressure recorded (B) at baseline, 
perfusion start, perfusion stop and sacrifice. Furthermore, no significant difference was recorded 
during continuous cardiac rhythm monitoring (C) or in heart rate recorded (D) at baseline, 
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